{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-25-000086","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.077100+00:00","generated_at":"2026-05-17T00:18:54.942102+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Keros net loss narrows to $7.3M in Q3; cash runway into H1 2028","bullets":["Net loss of $7.3M in Q3 2025 versus $53.0M in Q3 2024, driven by Takeda license revenue.","R&D expenses fell to $19.5M from $49.2M after elritercept transition to Takeda.","Cash and equivalents $693.5M; board authorized $375M return to stockholders.","Takeda plans to initiate Phase 3 trial of elritercept in first-line myelodysplastic syndromes.","Keros expects to fund operations into H1 2028 after capital return."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-25-000086","json":"https://secwatch.observer/filing/0001664710-25-000086.json","markdown":"https://secwatch.observer/filing/0001664710-25-000086.md","text":"https://secwatch.observer/filing/0001664710-25-000086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000086/0001664710-25-000086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000086/kros-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:18:54.942102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}